for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Synlogic Inc

SYBX.OQ

Latest Trade

2.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.38

 - 

10.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Synlogic Announces Termination Of Abbvie Collaboration Agreement

May 21 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC ANNOUNCES TERMINATION OF ABBVIE COLLABORATION AGREEMENT.SYNLOGIC INC - TERMINATION OF DEAL WITH ABBVIE FOR DEVELOPMENT OF SYNTHETIC BIOTIC MEDICINES FOR POTENTIAL TREATMENT OF INFLAMMATORY BOWEL DISEASE.SYNLOGIC INC - ABBVIE AND SYNLOGIC HAVE BEEN PROSECUTING SPECIFIED SYNTHETIC BIOTIC PROGRAMS THROUGH DISCOVERY ACTIVITIES.SYNLOGIC INC - ABBVIE, CO HAVE DECIDED TO TERMINATE THEIR COLLABORATION ON PROGRAMS.SYNLOGIC INC - SYNLOGIC FURTHER REGAINS RIGHTS TO PARTNER ITS IBD PROGRAMS.SYNLOGIC - UPON TERMINATION, SYNLOGIC REGAINS ALL RIGHTS TO DEVELOP PROGRAMS AND NEW IBD SYNTHETIC BIOTIC MEDICINES FOR ALL EFFECTORS TARGETING IBD.

Synlogic Provides Summary Of Impact Of COVID-19 On Clinical Program Progress And Operational Activities

March 30 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC PROVIDES SUMMARY OF IMPACT OF COVID-19 ON CLINICAL PROGRAM PROGRESS AND OPERATIONAL ACTIVITIES.SYNLOGIC INC - EXPECTS THAT ENROLLMENT OF SUBJECTS INTO ITS PLANNED PHASE 2 CLINICAL STUDY OF SYNB1618 WILL BE DELAYED.SYNLOGIC INC - EXPECTS SLOWER ENROLLMENT OF NEW SUBJECTS INTO ITS ONGOING PHASE 1 CLINICAL TRIAL OF SYNB1891.

Synlogic Files For Common Stock Offering Of Up To $17.3 Million

March 18 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC INC FILES FOR COMMON STOCK OFFERING OF UP TO $17.3 MILLION - SEC FILING.

Synlogic Reports Third Quarter Results

Nov 12 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC PROVIDES PROGRAM AND BUSINESS UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.39.Q3 REVENUE $300,000 VERSUS $1.8 MILLION.Q3 REVENUE ESTIMATE $381,000 -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.ENDS 3Q2019 WITH APPROXIMATELY $139 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS SUPPORTING PROJECTED RUNWAY THROUGH 2021.

Synlogic Commenced A Search For A Successor To Co's Prior CFO, Todd Shegog

Oct 25 (Reuters) - Synlogic Inc <SYBX.O>::ON OCT 21, APPOINTED GREGG BELOFF AS INTERIM CFO.COMMENCED A SEARCH FOR A SUCCESSOR TO CO'S PRIOR CFO, TODD SHEGOG.

Synlogic Announces Appointments Of New CMO, Head Of Regulatory Affairs, And CFO Departure

Sept 4 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC ANNOUNCES APPOINTMENTS OF NEW CMO, HEAD OF REGULATORY AFFAIRS, AND CFO DEPARTURE.SYNLOGIC INC - DEPARTURE OF TODD SHEGOG, CHIEF FINANCIAL OFFICER, EFFECTIVE SEPTEMBER 18.SYNLOGIC INC - COMMENCED A SEARCH FOR A NEW CFO.SYNLOGIC INC - TODD SHEGOG LEAVING COMPANY TO PURSUE ANOTHER OPPORTUNITY.

Synlogic Says Selling Stockholder May Offer And Resell Under This Prospectus Of Up To 8.9 Mln Shares Of Co's Common Stock

Aug 8 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC INC - SELLING STOCKHOLDER MAY OFFER AND RESELL UNDER THIS PROSPECTUS OF UP TO 8.9 MILLION SHARES OF COS' COMMON STOCK - SEC FILING.

Synlogic Q2 Loss Per Share $0.45

Aug 8 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES PROGRAM UPDATES.Q2 LOSS PER SHARE $0.45.Q2 REVENUE $400,000 VERSUS $300,000.Q2 EARNINGS PER SHARE ESTIMATE $-0.49 -- REFINITIV IBES DATA.Q2 REVENUE ESTIMATE $733,000 -- REFINITIV IBES DATA.

Synlogic Expects To Initiate SYNB1618 Efficacy Study In First Half Of 2020

July 15 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC REPORTS POSITIVE TOP-LINE DATA FROM PHASE 1/2A STUDY OF SYNB1618 IN PATIENTS WITH PHENYLKETONURIA AND GUIDES TO NEXT PHASE OF DEVELOPMENT.SYNLOGIC INC - DATA DEMONSTRATE STATISTICALLY SIGNIFICANT BIOMARKER ACTIVITY AT WELL-TOLERATED DOSE IN PKU PATIENTS.SYNLOGIC INC - PLAN TO INITIATE BRIDGING STUDY WITH NEW ORAL SOLID FORMULATION IN Q3 2019.SYNLOGIC INC - EXPECTS TO INITIATE SYNB1618 EFFICACY STUDY IN FIRST HALF OF 2020..

Synlogic And Ginkgo Bioworks Establish Platform Collaboration

June 12 (Reuters) - Synlogic Inc <SYBX.O>::SYNLOGIC AND GINKGO BIOWORKS ESTABLISH TRANSFORMATIONAL PLATFORM COLLABORATION FOR THE ACCELERATED DEVELOPMENT OF NOVEL SYNTHETIC BIOTIC™ MEDICINES.SYNLOGIC- AGREEMENT PROVIDES $80.0 MILLION EQUITY INVESTMENT AT A PREMIUM IN SYNLOGIC BY GINKGO AND ENTRY INTO LONG-TERM STRATEGIC PLATFORM COLLABORATION.SYNLOGIC-HAS EXCLUSIVE RIGHTS TO ANY SYNTHETIC BIOTIC MEDICINES IT DEVELOPS AS PART OF COLLABORATION & TO INTELLECTUAL PROPERTY COVERING SUCH PRODUCTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up